Skip to Content
Søg Menu

WCLC2020: Opløftende data for patienter med recidiverende malign mesotheliom

Hør Jens Benn Sørensen perspektivere resultaterne fra CONFIRM-studiet, der viser interessante data for behandling med nivolumab monoterapi til patienter med recidiverende malign mesotheliom.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Related

Medicinrådets anbefalinger

/ BestPractice Nordic
Nyt fra MedicinrådetBrystcancerLungecancerLungehindecancer

Dobbelt immunterapi forlænger fortsat overlevelsen ved malignt pleural mesotheliom

/ BestPractice Nordic
ESMO21LungehindecancerImmunterapi

Pembrolizumab plus chemotherapy provided durable clinical benefit in patients with metastatic squamous NSCLC

/ Martin Reck
WCLC20LungecancerImmunterapi Play the Video 8:48

Pembrolizumab with chemo-radiation therapy showed promising antitumor activity in unresectable, locally advanced, stage III NSCLC

/ Martin Reck
WCLC20LungecancerImmunterapi Play the Video 7:17

WCLC2020: Pembrolizumab significantly improved 5-year survival in patients with previously treated advanced NSCLC

/ Roy S. Herbst
WCLC20LungecancerImmunterapi Play the Video 2:25

Lovende responsrater med pembrolizumab i kombination med kemostrålebehandling til lokalavanceret NSCLC: 12 måneder data fra KEYNOTE-799

/ BestPractice Nordic
NSCLCWCLC20Lungecancer

WCLC2020: COVID-19 outcomes in patients with thoracic malignancies

/ Umit Tapan
WCLC20COVID-19 Play the Video 16:35

Lovende resultater med neoadjuvant atezolizumab til stadie IB-IIIB NSCLC

/ BestPractice Nordic
NSCLCWCLC20Lungecancer

WCLC2020: Pre-operative treatment with atezolizumab in untreated stage IB-IIIB resectable NSCLC

/ Jay M. Lee
WCLC20LungecancerImmunterapi Play the Video 10:38
Back to top